MetaCap

NRX Pharmaceuticals (NRXP) vs Unicycive Therapeutics (UNCY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NRX Pharmaceuticals (NRXP) has outperformed Unicycive Therapeutics (UNCY) over the past year, gaining 0.9% versus a loss of 38.0%. Over five years, UNCY leads with a -88.5% price change compared with -96.8% for NRXP. Unicycive Therapeutics is the larger company by market cap ($97.8 million vs $95.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NRXP+0.94%UNCY-37.96%
+125%+39%-46%
Nov 21, 20251 yearNov 20, 2026
NRXP-95.81%UNCY-87.07%
+38%-33%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NRXP versus UNCY key metrics
MetricNRXPUNCY
Share price$2.15$3.35
Market cap$95.31M$97.77M
1-day change-15.69%-5.10%
YTD return-20.66%-41.94%
1-year return+0.94%-37.96%
5-year return-96.81%-88.53%
Forward P/E—4.86
EPS (TTM)$-0.33$-1.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.23M—
Net income (latest FY)$-28.62M$-26.55M
Gross margin58.78%—
Operating margin-1324.41%—
Net margin-2336.49%—
52-week high$5.06$8.74
52-week low$1.62$3.33
Distance from 52-week high-57.47%-61.67%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1702.33%+685.07%
Average volume1.07M963.80K
Shares outstanding44.33M29.18M
Employees2921
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NRXP has outperformed UNCY by 38.9 percentage points over the past year.

About NRX Pharmaceuticals

NRXP stock →

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

About Unicycive Therapeutics

UNCY stock →

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

NRXP vs UNCY FAQ

Which is bigger, NRX Pharmaceuticals or Unicycive Therapeutics?

Unicycive Therapeutics (UNCY) is larger, with a market capitalization of $97.77M compared with $95.31M for NRX Pharmaceuticals (NRXP).

Which stock has performed better over the past year, NRXP or UNCY?

NRXP returned +0.94% over the past 12 months, compared with -37.96% for UNCY (price return, excluding dividends). Past performance does not predict future results.

Are NRX Pharmaceuticals and Unicycive Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons